Akshay T. Krishnamurty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Akshay T. Krishnamurty has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Sören Müller
Genentech, South San Francisco, CA, USA
18 shared publications - Rachana Pradhan
Genentech 1 Computational Sciences Center of Excellence South San Francisco, California
13 shared publications - Anwesha Dey
Genentech
12 shared publications - Bo Li
Genentech Research and Early Development, Genentech, Inc., South San Francisco, USA
12 shared publications - Danilo Maddalo
Department of Translational Oncology, Genentech, South San Francisco, CA, USA.
12 shared publications - Hamid Ghaedi
Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
12 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
Survival analysis for YAP/TAZ compared to other pathways
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
Survival analysis for YAP/TAZ compared to other pathways
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
Single cell pan-cancer atlas cluster specific genes.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
Single cell pan-cancer atlas cluster specific genes.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
Supplementary Methods for Firmament
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
Supplementary Methods for Firmament
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
Variance in Overall Response Rate per cell type
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
Variance in Overall Response Rate per cell type
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
Pan-cancer endothelial cell atlas
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
Pan-cancer endothelial cell atlas
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
Hippo pathway activity is predictive for poor cancer immunotherapy outcome
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
Hippo pathway activity is predictive for poor cancer immunotherapy outcome
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
The use of immunotherapy in solid tumors has significantly improved the outcomes and quality of life for patients with cancer. However, a substantial fraction of patients remains unresponsive, highlighting the urgent need to identify mechanisms of resistance to enhance immune-centric, chemo-free treatment regimens. In this study, we investigated associations with immunotherapy resistance by integrating RNA sequencing data from 2,800 patients with bladder cancer enrolled in the IMvigor trials, focusing on resistance to the anti–PD-L1 therapy atezolizumab, along with single-cell data from 200 patient samples and healthy donors. To expand the analysis to a massive collection of more than 100 million cells from hundreds of diverse single-cell studies, Firmament was developed as a method to efficiently identify cell populations that show enrichment for expression of gene signatures. These analyses identified the Hippo pathway as critically associated with immunotherapy resistance in bladder cancer and other solid tumors. Notably, Hippo dysregulation in stromal cells, rather than cancer cells, drove the high YAP/TAZ signal in these tumors, and Hippo signaling was specifically dysregulated in cancer-associated fibroblasts (CAF) compared with healthy donor fibroblasts. Inhibition of YAP signaling with a pan-TEAD inhibitor reduced expression of a myofibroblast gene program and decreased contractility of CAFs. Overall, this study provides insights that could aid in developing therapeutic combinations to improve outcomes for patients with solid tumors treated with immune checkpoint inhibitors.Significance:Clinical data indicate dysregulation of the Hippo pathway in cancer-associated fibroblasts is associated with anti-PD-L1 resistance, suggesting the potential of TEAD inhibitors in clinical development to overcome resistance to immune checkpoint therapy.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
The use of immunotherapy in solid tumors has significantly improved the outcomes and quality of life for patients with cancer. However, a substantial fraction of patients remains unresponsive, highlighting the urgent need to identify mechanisms of resistance to enhance immune-centric, chemo-free treatment regimens. In this study, we investigated associations with immunotherapy resistance by integrating RNA sequencing data from 2,800 patients with bladder cancer enrolled in the IMvigor trials, focusing on resistance to the anti–PD-L1 therapy atezolizumab, along with single-cell data from 200 patient samples and healthy donors. To expand the analysis to a massive collection of more than 100 million cells from hundreds of diverse single-cell studies, Firmament was developed as a method to efficiently identify cell populations that show enrichment for expression of gene signatures. These analyses identified the Hippo pathway as critically associated with immunotherapy resistance in bladder cancer and other solid tumors. Notably, Hippo dysregulation in stromal cells, rather than cancer cells, drove the high YAP/TAZ signal in these tumors, and Hippo signaling was specifically dysregulated in cancer-associated fibroblasts (CAF) compared with healthy donor fibroblasts. Inhibition of YAP signaling with a pan-TEAD inhibitor reduced expression of a myofibroblast gene program and decreased contractility of CAFs. Overall, this study provides insights that could aid in developing therapeutic combinations to improve outcomes for patients with solid tumors treated with immune checkpoint inhibitors.Significance:Clinical data indicate dysregulation of the Hippo pathway in cancer-associated fibroblasts is associated with anti-PD-L1 resistance, suggesting the potential of TEAD inhibitors in clinical development to overcome resistance to immune checkpoint therapy.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
Single cell datasets used for Firmament and the single cell atlas
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
Single cell datasets used for Firmament and the single cell atlas